Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Monday, May 08, 2017 | Personnel/Company News , Product Launches and Updates , Research and Publications


Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-related adverse events were reported. FCX-007 has been granted Orphan Drug, Rare Pediatric Disease and Fast Track Designations by the FDA. Fibrocell is developing FCX-007 in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology.

As specified in the protocol of this Phase 1/2 trial, additional adult patients can begin to be dosed with this recommendation from the DSMB. Six adult patients are targeted for the Phase 1 portion of the trial. Twelve-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in the Phase 1 portion of this trial are expected in the third quarter of 2017.

The primary objective of this open-label clinical trial is to evaluate the safety of FCX-007 in RDEB patients. Additionally, the trial will assess the mechanism of action of FCX-007 through evaluation of COL7 expression and the presence of anchoring fibrils, as well as the efficacy of FCX-007 through evidence of wound healing. Assessments are performed at 4-, 12-, 25- and 52-weeks post-administration of FCX-007. Six adult patients are targeted to be treated with FCX-007 in the Phase 1 portion of the trial and six pediatric patients in the Phase 2 portion of the trial. Prior to conducting clinical trials on pediatric patients, Fibrocell is required to obtain allowance from the FDA by submitting evidence of FCX-007 activity in adult patients and data from its completed pre-clinical toxicology study.

“We appreciate the DSMB’s support to continue the evaluation of our leading gene therapy candidate, FCX-007,” said John Maslowski, Chief Executive Officer of Fibrocell. “We look forward to dosing additional adult RDEB patients in the Phase 1 portion of the trial with this novel therapy that has the potential to be transformative for patients suffering from this devastating disease.”

Next Story

Comments

You must be logged in to leave a comment.